Americas In 2019 the pharma industry financed some 700 clinical studies in Latin America with investments of more than USD one billion and according to FIFARMA, the leading association of innovators in the region, LatAm currently supports about 10 percent of the world’s clinical research. Local industry leaders discuss the advantages…
Italy Giuseppe Maduri, Chairman, Managing Director, General Manager Italy, Greece, Cyprus, Malta at Astellas Pharma explains the Japanese company’s focus on unmet needs and how Italy, one of its top European markets, is working to ovecome market access challenges. Greater anticipation would allow patients’ faster access to innovation but requires a…
Astellas Pharma India Pvt. Ltd. When Astellas announced to expand its presence in India in 2009, you were already speaking of the company’s long commitment and solid relationship with India. Can you elaborate on these historical ties and how important it was to set up your India operations at that time? Since the former Fujisawa…
Astellas Pharma Ltd. South Africa The South African affiliate was established in June 2003. Could you come back on the main milestones in the company’s development from 2003 onwards? Yamanouchi as an entity was an agency in South Africa under Pharmaplan from 1996. In 1997 I joined Pharmaplan as the Managing Director and ran the…
Astellas Pharma Ltd. Astellas’s European headquarters is based in the UK. What does the UK market represent for the company? Speaking from a global perspective, 60% of Astellas’ business is based in Japan and Asia. Approximately 20% is in the U.S.; and approximately 20% is in Europe. So Europe still represents a vast—and…
Astellas Pharma Germany Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the two companies. Could you describe their integration process in Germany and which were the main synergies in the local market?…
See our Cookie Privacy Policy Here
